Erythropoietin (EPO) levels in fetal rats after ritodrine and terbutaline administration.
Beta-2 sympathomimetics, such as terbutaline, have been shown to alter erythropoietin (EPO) secretion in animal studies. More recently introduced sympathomimetics, such as ritodrine, have been extensively used to inhibit uterine contractions in preterm labor. It has not been determined what effect ritodrine may have on EPO production. We investigated the effect of RD administered to rats in the last day of gestation on the dam and the fetuses' levels of EPO. Rats at the 20th day of gestation were given, under anesthesia, either 3000 micrograms/kg ritodrine over a 10-min period or a similar volume of saline as control (CTL). Fetuses were removed at 0 and 4 h after injection. Ritodrine administration produced a decrease of dam EPO (23.4 +/- 4.2 to 12.0 +/- 2.9 pmol/ml), while the CTL showed no changes. The fetuses from the ritodrine-injected dams exhibited a marked decline over the 4-h period, while the CTL fetuses did not change. In other experiments 500 micrograms terbutaline was administered daily during the last 5 days of rat gestation. The drug produced a significant decline in EPO at delivery time, but plasma EPO in the pups was unchanged. Blood hematocrits were comparable to those of controls. The data show that acute administration of ritodrine reduces fetal and dam plasma EPO, while long-term terbutaline treatment late in gestation alters maternal, but not fetal plasma EPO, indicating that neither drug has any direct regulatory effect on the erythropoietic ability of the fetuses.